Companies don’t turn on a dime, and it’s not fair to attribute all of NuVasive’s (NUVA)
recent improvements to new management, but there has definitely been a
shift at NuVasive – not just in tone and priorities, but in delivered
performance as well. With NuVasive not only improving strongly upon its
core (the X360 platform) but also expanding into new areas (Pulse
Robotics), and showing improved operational execution, it’s no wonder
investors have come back to this name. I liked NuVasive in June,
and the shares are up about 35% since then, almost quintupling the
performance of the larger medical device segment. Although 2019 has
developed more or less as I expected from a modeling perspective, I’m
more bullish on the company’s near-to-medium-term future. Although the
stock already reflects this, this would certainly be a name to
reconsider on a pullback.
Read the full article here:
NuVasive At New Highs As New Management Has Quickly Built Credibility
No comments:
Post a Comment